IN THE SENATE OF THE UNITED STATES
January 28, 2021
Mrs. Shaheen (for herself, Mr. Brown, Mr. King, Ms. Hassan, Mr. Whitehouse, Ms. Baldwin, Mrs. Gillibrand, Mr. Van Hollen, Mr. Sanders, Mr. Reed, Ms. Klobuchar, Mr. Blumenthal, Ms. Warren, Ms. Hirono, Ms. Smith, Mr. Durbin, Mr. Bennet, Mrs. Feinstein, Mr. Manchin, Mr. Leahy, and Mr. Kaine) introduced the following bill; which was read twice and referred to the Committee on Finance
To amend the Internal Revenue Code of 1986 to deny the deduction for advertising and promotional expenses for prescription drugs.
This Act may be cited as the
End Taxpayer Subsidies for Drug Ads Act.
Disallowance of deduction for advertising and promotional expenses for prescription drugs
Part IX of subchapter B of chapter 1 of subtitle A of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:
Disallowance of deduction for direct-to-consumer advertising of prescription drugs
No deduction shall be allowed under this chapter for expenses relating to direct-to-consumer advertising of prescription drugs for any taxable year.
For purposes of this section, the term direct-to-consumer advertising means any dissemination, by or on behalf of a sponsor of a prescription drug product (as such term is defined in section 735(3) of the Federal Food, Drug, and Cosmetic Act), of an advertisement which—
is in regard to such prescription drug product, and
primarily targeted to the general public, including through—
publication in journals, magazines, other periodicals, and newspapers,
broadcasting through media such as radio, television, and telephone communication systems, direct mail, and billboards, and
dissemination on the Internet or through digital platforms (including social media, mobile media, web applications, digital applications, mobile applications, and electronic applications).
The table of sections for such part IX of the Internal Revenue Code of 1986 is amended by adding after the item relating to section 280H the following new item:
Sec. 280I. Disallowance of deduction for direct-to-consumer advertising of prescription drugs.
The amendments made by this section shall apply to amounts paid or incurred after the date of the enactment of this Act, in taxable years ending after such date.